The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Ivosidenib in mIDH1 CCA: data from the Italian population in the ProvIDHe study
Lorenza Rimassa, MD, Hunimed University, Milan, Italy, explores findings from the Italian population of the Phase IIIb ProvIDHe study (NCT05876754) examining ivosidenib in patients with IDH1 mutated cholangiocarcinoma (mIDH1 CCA). Results in the Italian population were the same as in the global population, supporting the use of ivosidenib in clinical practice in patients with IDH1 mutations. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
